Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Chronic spontaneous urticaria

Economic burden and healthcare resource utilization

9 evidence topics · 9 sources

ASSURE-CSU: direct, indirect, and out-of-pocket costs by country and resource use

“Total average (SD) annual direct costs per patient per year, as captured in the retrospective medical record review, ranged from PPP$907.1 ($2431.14) in Italy to PPP$2984.2 ($8969.46) in France. The major drivers of these costs were therapies (range, PPP$426.4‐$1788.7) and inpatient visits (range, PPP$250.7‐$1074.4) (Tables S5 and S6 in Appendix S5 and S6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Average indirect costs, or costs of patient‐reported total work productivity loss over 4 weeks, were driven primarily by the cost of presenteeism (range, PPP$544.5‐$1180.0); the mean (SD) cost of work productivity loss ranged from PPP$544.8 ($603.22) in France to PPP$1287.4 ($1123.80) in Germany (Table S7 in Appendix S7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Moreover, in ASSURE‐CSU, CSU‐related out‐of‐pocket expenses to patients averaged nearly PPP$500 per year and approached PPP$1000 in Canada.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among the 97 patients (14.4%) with at least one CSU‐related ED visit in the past 12 months, the annual mean (SD) number of visits was 1.8 (1.26). Hospitalization for CSU was recorded for 55 patients (8.2%), with a mean (SD) length of stay per hospitalization of 3.7 (2.67) days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote